Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib in advanced extrapancreatic neuroendocrine tumors
NCT02588170Phase 3Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Dec 2015
- Primary completion
- Mar 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of surufatinib in Neuroendocrine Neoplasm (NEN), sponsored by Hutchison MediPharma (HMP). Started Dec 2015; status: completed.
02
Drugs
surufatinib
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT02588170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588170.